Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC
Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with
Bruton's Tyrosine Kinase Inhibitors
SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with its
Bruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...
Pharmacyclics Announces Presentations on Its Novel and Selective
HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds
SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ --Pharmacyclics, Inc. announced today multiple presentationsregarding its novel histone deacetylase (HDAC) inhibitor and
Bruton's tyrosine kinase inhibitor compounds. The presentationswill take place at the American Association for Cancer Research(AACR) 2007 Annual Meeting being held April 14-18, 2007, at the LosAngeles Convention C...